### Table 1.23

Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites<sup>a</sup> by Race/Ethnicity

### Both Sexes

All Races			White			Black		
	Rate <sup>b</sup>	APC <sup>c</sup>		Rate <sup>b</sup>	APC <sup>c</sup>		Rate <sup>b</sup>	APC <sup>c</sup>
	2004-2008	1999-2008		2004-2008	1999-2008		2004-2008	1999-2008
All Sites	464.4	-0.7*	All Sites	471.8	-0.7*	All Sites	491.2	-1.0*
Prostate <sup>f</sup>	69.7	-1.6*	Breast	68.2	-1.8*	Prostate <sup>f</sup>	97.4	-2.5*
Breast	67.0	-1.4*	Prostate <sup>f</sup>	67.4	-1.7*	Lung and Bronchus	72.7	-1.8*
Lung and Bronchus	62.0	-1.3*	Lung and Bronchus	63.3	-1.2*	Breast	68.8	0.1
Colon and Rectum	47.2	-2.4*	Colon and Rectum	46.5	-2.6*	Colon and Rectum	57.8	-1.8*
Urinary Bladder	21.1	-0.4*	Melanoma of the Skin	24.3	2.3*	Kidney and Renal Pelvis	16.5	2.9*
Melanoma of the Skin	20.8	1.9*	Urinary Bladder	22.9	-0.4	Pancreas	15.9	0.9
Non-Hodgkin Lymphoma	19.8	0.2	Non-Hodgkin Lymphoma	20.7	0.2	Non-Hodgkin Lymphoma	14.8	0.6
Kidney and Renal Pelvis	14.6	3.0*	Kidney and Renal Pelvis	15.1	2.8*	Urinary Bladder	13.1	-0.3
Corpus and Uterus, ${ m NOS}^{ m f}$	12.8	-0.1	Corpus and Uterus, ${ m NOS}^{ m f}$	13.2	-0.4	Corpus and Uterus, NOS <sup>f</sup>	12.0	2.2*
Leukemia	12.5	-0.4	Leukemia	13.1	-0.4	Stomach	11.9	-1.6*
Pancreas	12.0	1.1*	Pancreas	11.9	1.1*	Myeloma	11.9	0.4
Thyroid	11.0	6.2*	Thyroid	11.5	6.4*	Oral Cavity and Pharynx	9.9	-2.8*
Oral Cavity and Pharynx	10.6	-0.4	Oral Cavity and Pharynx	10.8	-0.1	Leukemia	9.8	-1.1
Stomach	7.7	-1.6*	Ovary <sup>fh</sup>	7.2	-1.8*	Liver & IBD <sup>g</sup>	9.2	3.6*
Liver & IBD <sup>g</sup>	7.3	3.0*	Brain and ONS <sup>g</sup>	7.1	-0.5	Thyroid	6.5	6.1*
Asian/Pacific Islander			American Indian/Alaska Native <sup>d</sup>			Hispanic <sup>e</sup>		
	Rate <sup>b</sup>	APC <sup>c</sup>		Rate <sup>b</sup>	APC <sup>c</sup>		Rate <sup>b</sup>	APC <sup>c</sup>
	2004-2008			2004-2008	1999-2008		2004-2008	1999-2008
All Sites	315.9	-0.4*	All Sites	319.9	-0.6	All Sites	356.1	-0.8*
Breast	51.2	0.5	Lung and Bronchus	44.5	0.4	Prostate <sup>f</sup>	56.8	-2.2*
Colon and Rectum	39.4	-1.9*	Breast	42.3	0.1	Breast	49.0	-0.7*
Lung and Bronchus	39.0	-0.9*	Colon and Rectum	41.4	-2.3	Colon and Rectum	38.3	-1.0*
Prostate <sup>f</sup>	38.4	-2.0*	Prostate <sup>f</sup>	33.0	-1.9	Lung and Bronchus	32.5	-1.5*
Liver & IBD <sup>g</sup>	14.6	0.5	Kidney and Renal Pelvis	17.6	3.3*	Non-Hodgkin Lymphoma	17.2	0.3
Non-Hodgkin Lymphoma	13.3	-0.5	Liver & IBD <sup>g</sup>	12.2	3.4	Kidney and Renal Pelvis	14.5	2.9*
Stomach	13.0	-3.1*	Non-Hodgkin Lymphoma	11.5	-1.4	Urinary Bladder	11.6	-1.0
Thyroid	10.9	5.0*	Pancreas	10.6	1.6	Stomach	11.5	-1.8*
Corpus and Uterus, NOS <sup>f</sup>	9.9	1.8*	Stomach	10.6	-5.0	Liver & IBD <sup>g</sup>	11.1	2.0*
Pancreas	9.5	1.2*	Corpus and Uterus, ${ m NOS}^{ m f}$	9.0	0.8	Pancreas	10.9	0.7
Urinary Bladder	9.3	0.4	Urinary Bladder	8.3	-	Corpus and Uterus, NOS <sup>f</sup>	10.0	1.4*
Oral Cavity and Pharynx	7.9	-0.5	Leukemia	7.6	1.5	Leukemia	9.8	0.4
Kidney and Renal Pelvis	7.7	4.9*	Oral Cavity and Pharynx	7.0	-4.0	Thyroid	9.4	5.0*
Leukemia	7.3	-0.6	Thyroid	6.3	0.8	Ovary <sup>fh</sup>	6.3	-0.9
Ovary <sup>fh</sup>	5.4	-0.3	Ovary <sup>fh</sup>	5.8	-4.0	Oral Cavity and Pharynx	6.2	-0.7

Top 15 cancer sites selected based on 2004-2008 age-adjusted rates for the race/ethnic group.

b Incidence data used in calculating the rates are from the 17 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

The APC is the Annual Percent Change over the time interval. Incidence data used in calculating the trends are from the 13 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

d Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties. е

Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. f

The rates for sex-specific cancer sites are calculated using the population for both sexes combined. q

IBD = Intrahepatic Bile Duct. ONS = Other Nervous System. h

Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

The APC is significantly different from zero (p<.05).

Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

С

#### Table 1.24

Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites<sup>a</sup> by Race/Ethnicity

#### Males

All Races			White			Black			
	Rate <sup>b</sup>	APC <sup>c</sup>		Rate <sup>b</sup>	APC <sup>c</sup>		Rate <sup>b</sup>	APC <sup>c</sup>	
	2004-2008	1999-2008		2004-2008	1999-2008		2004-2008	1999-2008	
All Sites	541.0	-1.0*	All Sites	543.6	-1.0*	All Sites	626.1	-1.8*	
Prostate	156.0	-2.0*	Prostate	149.5	-2.2*	Prostate	233.8	-2.7*	
Lung and Bronchus	75.2	-2.1*	Lung and Bronchus	75.3	-2.1*	Lung and Bronchus	99.8	-2.8*	
Colon and Rectum	55.0	-2.7*	Colon and Rectum	54.4	-2.9*	Colon and Rectum	67.7	-1.8*	
Urinary Bladder	37.5	-0.4	Urinary Bladder	40.6	-0.4	Kidney and Renal Pelvis	23.3	3.0*	
Melanoma of the Skin	26.7	2.0*	Melanoma of the Skin	30.9	2.3*	Urinary Bladder	21.6	0.4	
Non-Hodgkin Lymphoma	24.0	0.1	Non-Hodgkin Lymphoma	25.0	0.2	Non-Hodgkin Lymphoma	17.9	0.0	
Kidney and Renal Pelvis	20.0	2.8*	Kidney and Renal Pelvis	20.5	2.5*	Stomach	17.2	-0.7	
Leukemia	16.1	-0.8*	Leukemia	16.8	-0.8	Pancreas	17.1	0.5	
Oral Cavity and Pharynx	15.7	-0.4	Oral Cavity and Pharynx	16.1	-0.1	Oral Cavity and Pharynx	15.6	-3.3*	
Pancreas	13.6	1.1*	Pancreas	13.5	1.1*	Liver & IBD <sup>f</sup>	15.1	3.8*	
Liver & IBD <sup>f</sup>	11.2	3.2*	Liver & IBD <sup>f</sup>	9.6	3.7*	Myeloma	14.5	0.5	
Stomach	10.8	-1.8*	Stomach	9.5	-1.9*	Leukemia	12.9	-0.5	
Esophagus	7.8	-0.8	Brain and $ONS^{f}$	8.4	-0.6	Larynx	9.8	-3.9*	
Brain and ONS <sup>f</sup>	7.7	-0.6*	Esophagus	8.1	-0.4	Esophagus	8.6	-4.1*	
Myeloma	7.2	-0.2	Myeloma	6.8	-0.2	Brain and ONS <sup>f</sup>	4.6	-1.3	
Asian/Pacific	Asian/Pacific Islander			American Indian/Alaska Native <sup>d</sup>			Hispanic <sup>e</sup>		
	Rate <sup>b</sup>	APC <sup>c</sup>		Rate <sup>b</sup>	APC <sup>c</sup>		Rate <sup>b</sup>	APC <sup>c</sup>	
	2004-2008	1999-2008			1999-2008		2004-2008	1999-2008	
All Sites	347.7	-1.1*	All Sites	338.0	-1.3	All Sites	407.3	-1.5*	
Prostate	88.3	-2.0*	Prostate	75.3	-1.7	Prostate	129.0	-2.8*	
Lung and Bronchus	53.2	-1.3*	Lung and Bronchus	51.2	0.0	Colon and Rectum	46.0	-1.5*	
Colon and Rectum	45.4	-2.2*	Colon and Rectum	42.7	-3.7	Lung and Bronchus	41.5	-2.2*	
Liver & IBD <sup>f</sup>	22.1	0.6	Kidney and Renal Pelvis	22.1	3.1	Urinary Bladder	20.0	-1.8*	
Stomach	17.2	-3.1*	Liver & IBD <sup>f</sup>	17.4	2.5	Non-Hodgkin Lymphoma	19.5	0.2	
Non-Hodgkin Lymphoma	16.3	-0.4	Stomach	14.7	-3.9	Kidney and Renal Pelvis	19.2	2.8*	
Urinary Bladder	16.3	0.4	Urinary Bladder	14.0	-	Liver & IBD <sup>f</sup>	16.5	2.2*	
Oral Cavity and Pharynx	10.9	0.1	Non-Hodgkin Lymphoma	13.0	-	Stomach	14.9	-1.9	
Kidney and Renal Pelvis	10.6	5.0*	Pancreas	11.4	-	Leukemia	11.7	-0.5	
Pancreas	10.6	2.1*	Leukemia	9.1	-	Pancreas	11.4	1.3	
Leukemia	8.9	-1.8*	Oral Cavity and Pharynx	9.1	-	Oral Cavity and Pharynx	9.0	-0.9	
Thyroid	4.9	3.1*	Esophagus	5.9	-	Myeloma	6.4	-1.2	
Esophagus	4.2	-1.4	Myeloma	4.9	-	Brain and ONS <sup>f</sup>	6.0	-1.2	
Myeloma	4.1	-0.3	Melanoma of the Skin	3.9	-	Esophagus	5.2	-4.5*	
Brain and ONS <sup>f</sup>	4.0	-0.2	Brain and $ONS^{f}$	3.8	-	Melanoma of the Skin	4.8	0.6	

а Top 15 cancer sites selected based on 2004-2008 age-adjusted rates for the race/ethnic group. h

Incidence data used in calculating the rates are from the 17 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

The APC is the Annual Percent Change over the time interval. Incidence data used in calculating the trends are from the 13 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). d

Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

P Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. f

IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

The APC is significantly different from zero (p<.05).

Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

с

#### Table 1.25

Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites<sup>a</sup> by Race/Ethnicity

#### Females

All Races			White			Black		
	Rate <sup>b</sup>	APC <sup>c</sup>		Rate <sup>b</sup>	APC <sup>c</sup>		Rate <sup>b</sup>	APC <sup>c</sup>
	2004-2008	1999-2008		2004-2008	1999-2008		2004-2008	1999-2008
All Sites	411.6	-0.4*	All Sites	423.0	-0.5*	All Sites	400.9	-0.2
Breast	124.0	-1.2*	Breast	127.3	-1.6*	Breast	119.9	0.1
Lung and Bronchus	52.3	-0.4	Lung and Bronchus	54.6	-0.4	Lung and Bronchus	54.7	-0.6
Colon and Rectum	41.0	-2.1*	Colon and Rectum	40.2	-2.2*	Colon and Rectum	51.2	-1.9*
Corpus and Uterus, NOS	23.9	0.2	Corpus and Uterus, NOS	24.8	-0.1	Corpus and Uterus, NOS	20.9	2.3*
Melanoma of the Skin	16.7	1.8*	Melanoma of the Skin	19.7	2.2*	Pancreas	14.8	1.4
Non-Hodgkin Lymphoma	16.5	0.2	Non-Hodgkin Lymphoma	17.3	0.2	Non-Hodgkin Lymphoma	12.3	1.1
Thyroid	16.3	6.6*	Thyroid	17.2	6.8*	Kidney and Renal Pelvis		2.7*
Ovary <sup>g</sup>	12.8	-1.5*	Ovary <sup>g</sup>	13.5	-1.7*	Myeloma	10.2	0.5
Pancreas	10.7	1.2*	Kidney and Renal Pelvis		3.1*	Ovary <sup>g</sup>	10.0	-0.2
Kidney and Renal Pelvis		3.1*	Pancreas	10.5	1.2*	Cervix Uteri	10.0	-4.1*
Leukemia	9.7	0.0	Leukemia	10.2	-0.2	Thyroid	9.3	6.3*
Urinary Bladder	9.2	-0.9*	Urinary Bladder	9.8	-0.9*	Stomach	8.5	-2.3*
Cervix Uteri	8.1	-2.6*	Cervix Uteri	8.0	-2.5*	Leukemia	7.8	-1.6
Oral Cavity and Pharynx		-0.6	Oral Cavity and Pharynx		-0.5	Urinary Bladder	7.6	-1.4
Stomach	5.4	-1.5*	Brain and $ONS^{f}$	5.9	-0.4	Oral Cavity and Pharynx	5.6	-1.4
Asian/Pacific Islander			American Indian/Alaska Native <sup>d</sup>			Hispanic <sup>e</sup>		
	Rate <sup>b</sup>	APC <sup>c</sup>		Rate <sup>b</sup>	APC <sup>c</sup>		Rate <sup>b</sup>	APC <sup>c</sup>
		1999-2008		2004-2008	1999-2008		2004-2008	1999-2008
All Sites	297.0	0.2	All Sites	309.0	0.1	All Sites	324.4	-0.1
Breast	93.7	0.5	Breast	77.9	0.0	Breast	92.1	-0.3
Colon and Rectum	34.6	-1.6*	Colon and Rectum	40.0	-1.1	Colon and Rectum	32.3	-0.7
Lung and Bronchus	28.5	-0.1	Lung and Bronchus	39.5	1.0	Lung and Bronchus	26.1	-0.7
Corpus and Uterus, NOS	18.2	1.8*	Corpus and Uterus, NOS	16.7	1.0	Corpus and Uterus, NOS	18.9	1.8*
Thyroid	16.4	5.5*	Kidney and Renal Pelvis	13.9	4.0	Non-Hodgkin Lymphoma	15.3	0.5
Non-Hodgkin Lymphoma	10.9	-0.5	Ovary <sup>g</sup>	10.6	-4.2	Thyroid	15.0	5.7*
Stomach	9.9	-3.0*	Non-Hodgkin Lymphoma	10.3	-	Cervix Uteri	12.2	-4.6*
Ovary <sup>g</sup>	9.9	-0.4	Pancreas	10.0	-	Ovary <sup>g</sup>	11.6	-0.6
Pancreas	8.6	0.2	Thyroid	9.4	0.5	Kidney and Renal Pelvis	10.7	3.0*
Liver & IBD <sup>f</sup>	8.4	0.3	Liver & IBD <sup>f</sup>	7.8	-	Pancreas	10.4	0.2
Cervix Uteri	7.3	-3.0*	Cervix Uteri	7.8	0.4	Stomach	9.0	-1.8*
Leukemia	6.1	0.9	Stomach	7.4	-	Leukemia	8.4	1.3

<sup>a</sup> Top 15 cancer sites selected based on 2004-2008 age-adjusted rates for the race/ethnic group.

Leukemia

Myeloma

Incidence data used in calculating the rates are from the 17 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

6.5

5.1

4.3

\_

\_

\_

Liver & IBD<sup>f</sup>

Urinary Bladder

Melanoma of the Skin

6.4

5.4

4.8

0.7

0.1

-0.9

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). The APC is the Annual Percent Change over the time interval. Incidence data used in calculating the trends are from the SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Oral Cavity and Pharynx

- <sup>d</sup> Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
- <sup>e</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
- f IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

4.7\*

-1.4

0.8

5.4

5.3

4.0

- <sup>g</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.
- The APC is significantly different from zero (p<.05).
- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Kidney and Renal Pelvis

Oral Cavity and Pharynx

Urinary Bladder

# SEER Incidence 1999-2008 Males by Race/Ethnicity





Figure 1.13

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). Regression lines are calculated using the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute.

- <sup>a</sup> Incidence rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA(Contract Health Service Delivery Area) counties.
- <sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

## SEER Incidence 1999-2008 Females by Race/Ethnicity



Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). Regression lines are calculated using the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute.

- <sup>a</sup> Incidence rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA(Contract Health Service Delivery Area) counties.
- <sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.